Trial · NCT00147264
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | (for both interventions): change in IMCL content in the soleus muscle as assessed by 1H-MRI Spectroscopy at baseline and 6 months | ||
| Secondary | Change in intra-hepatocellular lipid storage as assessed by 1H-MRI Spectroscopy | ||
| Secondary | Change in insulin sensitivity as determined by HOMA index | ||
| Secondary | Reversal of IFG to normal fasting glucose in participants with IFG | ||
| Secondary | Change in 72-hour subcutaneous glucose profile | ||
| Secondary | Change in fasting lipid profile (free fatty acids, triglyceride, total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol) | ||
| Secondary | Change in serum/plasma levels of inflammatory markers (C-reactive protein, adiponectin, tumor necrosis factor a, interleukin 6, leptin, adhesion molecules, plasminogen-activation inhibitor-1, t-PA, global test of fibrinolysis, fibrinogen, homocysteine, | ||
| Secondary | Change in beta-cell function as assessed by the Insulin Secretion Index | ||
| Secondary | Other efficacy parameters of the AT1 blockade and LGI diet are: | ||
| Secondary | Change in waist circumference | ||
| Secondary | Change in body composition as assessed by bioelectrical impedance analysis | ||
| Secondary | Change in abdominal (visceral) adipose tissue as assessed by MRI | ||
| Secondary | Change in resting blood pressure | ||
| Secondary | Change in adipocytic cell size determined by grouped diameter distribution in subcutaneous abdominal adipose tissue biopsies | ||
| Secondary | Changes in mRNA expression of genes in adipose tissue for genes involved in adipose tissue differentiation, growth, metabolism, cardiovascular function and inflammation. | ||
| Secondary | Change in muscle triglyceride content (histochemical examination of muscle biopsies) | ||
| Secondary | Change in molecular markers of endoplasmic reticular stress in circulating blood cells | ||
| Secondary | Endothelial function as assessed by Doppler ultrasound of the forearm blood flow. | ||
| Secondary | Systolic and diastolic cardiac function as assessed by echocardiography |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00147264/registered